Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer
Jorge A. Carrasquillo(Memorial Sloan Kettering Cancer Center), Michael J. Morris(The University of Texas Southwestern Medical Center), Steven M. Larson(Memorial Sloan Kettering Cancer Center), Susan F. Slovin(Cornell University), Joseph A. O’Donoghue(Memorial Sloan Kettering Cancer Center), John L. Humm(Memorial Sloan Kettering Cancer Center), Kristine Peregrino Lacuna(Memorial Sloan Kettering Cancer Center), Howard I. Scher(Kantonsspital Baselland Standort Bruderholz), Matthew J. Williamson(Memorial Sloan Kettering Cancer Center), Dana E. Rathkopf(Memorial Sloan Kettering Cancer Center), Anne-Kirsti Aksnes(Bayer (Norway)), Neeta Pandit‐Taskar(Memorial Sloan Kettering Cancer Center)
Cited by 182
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k